United Therapeutics Corp (UTHR.O)
5 May 2015
- The Food and Drug Administration said it approved United Therapeutics Corp's drug to treat neuroblastoma, a rare cancer that typically occurs in children below 5 years.
* Analyst expects drug to cost $150,000 per patient per year (Adds analyst comment, background)
March 10 - The U.S. Food and Drug Administration said it had approved United Therapeutics Corp's drug to treat neuroblastoma, a rare form of cancer that most often occurs in young children.
|Nippon Shinyaku Co., Ltd. (4516.T)||¥3,995||+5.00|
|Pfizer Inc. (PFE.N)||$34.12||-0.20|
|Novartis AG (NOVN.VX)||CHF94.75||--|
|Bayer AG (BAYGn.DE)||€126.45||--|
|Bayer AG (BAYE.F)||--||--|
|GlaxoSmithKline plc (GSK.L)||1,500.50p||--|
|Teva Pharmaceutical Industries Limited (TEVA.TA)||23,900.00₪||--|
|Gilead Sciences, Inc. (GILD.OQ)||$102.99||-2.67|
|Actelion Ltd (ATLN.VX)||CHF124.10||--|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Trading Report for (UTHR). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: New Constructs, LLC
"The Economy Matters" Report for UTHR: the economy's impact on UTHR's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.